{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:10:32Z","timestamp":1758593432125,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.neurol.2023.03.020","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T22:50:37Z","timestamp":1690325437000},"page":"925-927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atypical multiple sclerosis associated with indolent systemic mastocytosis treated by cladribine"],"prefix":"10.1016","volume":"179","author":[{"given":"P.","family":"Guillaume-Jugnot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-1829","authenticated-orcid":false,"given":"N.","family":"Shor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6388","authenticated-orcid":false,"given":"F.","family":"Bielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zavanone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Barete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-0328","authenticated-orcid":false,"given":"E.","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurol.2023.03.020_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clineuro.2011.05.002","article-title":"Neurologic symptoms and diagnosis in adults with mast cell disease","volume":"113","author":"Smith","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.020_bib0035","first-page":"2878","article-title":"Neuroinflammatory disorders and mastocytosis: a possible association?","volume":"7","author":"Rodrigues","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.020_bib0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.4103\/1673-5374.282238","article-title":"Should mast cells be considered therapeutic targets in multiple sclerosis?","volume":"15","author":"Pinke","year":"2020","journal-title":"Neural Regen Res"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.020_bib0045","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.020_bib0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872300975X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872300975X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:47:45Z","timestamp":1758520065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872300975X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S003537872300975X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.020","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical multiple sclerosis associated with indolent systemic mastocytosis treated by cladribine","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}